TW201402143A - 抗登革熱病毒疫苗之組成物及投藥方法 - Google Patents

抗登革熱病毒疫苗之組成物及投藥方法 Download PDF

Info

Publication number
TW201402143A
TW201402143A TW102120553A TW102120553A TW201402143A TW 201402143 A TW201402143 A TW 201402143A TW 102120553 A TW102120553 A TW 102120553A TW 102120553 A TW102120553 A TW 102120553A TW 201402143 A TW201402143 A TW 201402143A
Authority
TW
Taiwan
Prior art keywords
dengue
virus
vaccine composition
vaccine
administration
Prior art date
Application number
TW102120553A
Other languages
English (en)
Chinese (zh)
Inventor
Dan T Stinchcomb
Jorge E Osorio
Charalambos D Partidos
Joseph N Brewoo
Original Assignee
Inviragen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/492,884 external-priority patent/US8968996B2/en
Application filed by Inviragen Inc filed Critical Inviragen Inc
Publication of TW201402143A publication Critical patent/TW201402143A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW102120553A 2012-06-10 2013-06-10 抗登革熱病毒疫苗之組成物及投藥方法 TW201402143A (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13/492,884 US8968996B2 (en) 2009-06-01 2012-06-10 Compositions and methods for rapid immunization against dengue virus

Publications (1)

Publication Number Publication Date
TW201402143A true TW201402143A (zh) 2014-01-16

Family

ID=48652375

Family Applications (1)

Application Number Title Priority Date Filing Date
TW102120553A TW201402143A (zh) 2012-06-10 2013-06-10 抗登革熱病毒疫苗之組成物及投藥方法

Country Status (6)

Country Link
EP (1) EP2858668A1 (enrdf_load_stackoverflow)
JP (2) JP2015520196A (enrdf_load_stackoverflow)
CA (1) CA2915027A1 (enrdf_load_stackoverflow)
NZ (1) NZ630831A (enrdf_load_stackoverflow)
TW (1) TW201402143A (enrdf_load_stackoverflow)
WO (1) WO2013188315A1 (enrdf_load_stackoverflow)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108066756A (zh) * 2016-11-15 2018-05-25 吴夙钦 对抗复数种登革热病毒血清型的疫苗套组及其制备方法与用途

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2933472A1 (en) 2012-12-14 2014-06-19 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
SG10201913435TA (en) 2013-03-15 2020-03-30 Takeda Vaccines Inc Compositions and methods for dengue virus chimeric constructs in vaccines
CA2991212A1 (en) 2015-07-02 2017-01-05 PrimeVax Immuno-Oncology, Inc. Compositions and methods for combination therapy with dengue virus and dendritic cells
JP2018535191A (ja) 2015-09-26 2018-11-29 プライムヴァックス イミュノ−オンコロジー,インク. 樹状細胞を産生するための組成物及び方法
KR102611235B1 (ko) * 2016-04-13 2023-12-08 다케다 백신즈 인코포레이티드 어린이 및 젊은 성인에서 뎅기 바이러스에 대한 백신접종 조성물 및 방법
CA3082779A1 (en) 2016-11-16 2018-05-24 PrimeVax Immuno-Oncology, Inc. Combination immunotherapies for treatment of cancer
EP3565567A4 (en) 2017-01-04 2020-07-29 Primevax Immuno-Oncology, Inc. COMPOSITIONS AND METHODS OF THERAPY WITH DENGUE VIRUS
EP3620174B1 (en) 2018-09-05 2022-01-19 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8110196B2 (en) * 2005-04-29 2012-02-07 Polytopas LLC Methods and compositions for polytopic vaccination
FR2906724B1 (fr) * 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
JP5848243B2 (ja) * 2009-06-01 2016-01-27 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. デングウイルスに対する免疫原性組成物
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108066756A (zh) * 2016-11-15 2018-05-25 吴夙钦 对抗复数种登革热病毒血清型的疫苗套组及其制备方法与用途
CN108066756B (zh) * 2016-11-15 2021-07-06 吴夙钦 对抗复数种登革热病毒血清型的疫苗套组及其制备方法与用途

Also Published As

Publication number Publication date
JP2015520196A (ja) 2015-07-16
NZ630831A (en) 2019-02-22
CA2915027A1 (en) 2013-12-19
EP2858668A1 (en) 2015-04-15
WO2013188315A1 (en) 2013-12-19
JP2018090618A (ja) 2018-06-14

Similar Documents

Publication Publication Date Title
US9713638B2 (en) Compositions and methods for rapid immunization against dengue virus
Fahimi et al. Dengue viruses and promising envelope protein domain III-based vaccines
TW201402143A (zh) 抗登革熱病毒疫苗之組成物及投藥方法
Osorio et al. Development of DENVax: a chimeric dengue-2 PDK-53-based tetravalent vaccine for protection against dengue fever
JP5227172B2 (ja) デングウイルス感染に対するワクチン接種
US20130095136A1 (en) Tetravalent Dengue Vaccines
CA2505942C (en) West nile virus vaccine
US10010600B2 (en) Compositions and methods for administration of vaccines against dengue virus
US9878031B2 (en) Compositions, methods of administration and uses for trivalent dengue virus formulations
US20190194260A1 (en) Live attenuated zika virus vaccine
JP2007525226A (ja) フラビウイルスワクチン
WO2014204892A1 (en) Dengue virus vaccine compositions and methods of use thereof
CN105473603A (zh) 用于登革病毒疫苗的方法与组合物
CN106999568A (zh) 登革病毒疫苗组合物及其使用方法
Yan et al. Advancements in dengue vaccines: A historical overview and prospects for following next-generation candidates
Wu et al. Induction of cross-protection against two wild-type Taiwanese isolates of Japanese encephalitis virus using Beijing-1 strain DNA vaccine
JP2021168672A (ja) デングウイルス弱毒株をバンク化した生ウイルス、及びそれらを抗原とするデングワクチン
Gyawali et al. Vaccine development against dengue, a viral disease of increasing significance to global public health
Barrett Vaccines against flaviviruses
Shahana et al. Japanese Encephalitis: An overview of vaccine development